Skip to main content Back to Top
Advertisement

12/2/2022

Cytarabine Injection

Products Affected - Description

    • Cytarabine solution for injection, Pfizer, 100 mg/mL, 20 mL preservative-free vial, 1 count, NDC 61703-0319-22
    • Cytarabine solution for injection, Pfizer, 20 mg/mL, 50 mL preservative-free vial, 1 count, NDC 61703-0303-46

Reason for the Shortage

    • Fresenius Kabi has cytarabine on shortage due to a manufacturing delay.
    • Meitheal Pharmaceuticals had cytarabine on shortage due to a manufacturing delay.
    • Mylan Institutional has discontinued cytarabine presentations.
    • Pfizer had cytarabine on shortage due to increased demand.

Available Products

    • Cytarabine solution for injection, Fresenius Kabi, 100 mg/mL, 20 mL preservative-free vial, 1 count, NDC 63323-0120-20
    • Cytarabine solution for injection, Meitheal Pharmaceuticals, 100 mg/mL, 20 mL preservative-free vial, 1 count, NDC 71288-0109-20
    • Cytarabine solution for injection, Pfizer, 20 mg/mL, 25 mL multiple dose vial, 1 count, NDC 61703-0304-36
    • Cytarabine solution for injection, Pfizer, 20 mg/mL, 5 mL preservative-free vial, 5 count, NDC 61703-0305-38

Estimated Resupply Dates

    • Pfizer has cytarabine 20 mg/mL 50 mL vials and 100 mg/mL 20 mL vials available in limited supply.

Updated

Updated December 2, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 1, 2021 by Stephen Andrews, PharmD, BCPS, CPPS, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.